Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

Enduring CME activity from the September 4, 2018, Live Webcast: Meeting Unmet Clinical Needs in Cervical Cancer: Paving a New Course in Advanced Disease Settings With Immune-Based Strategies


Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based

Activity Overview

This enduring CME activity is an archive of the live broadcast from September 4, 2018, titled Meeting Unmet Clinical Needs in Cervical Cancer: Paving a New Course in Advanced Disease Settings With Immune-Based Strategies. This activity features a panel of gynecologic oncology experts providing you with a multifaceted overview of the application of immune-based strategies in the care of patients with advanced cervical cancer. During the webcast, the faculty discuss many aspects of the use of immunotherapies for the management of this disease, presenting divergent views of complex and controversial topics, thereby providing you with a more comprehensive understanding of the issues and informing your clinical decision-making.

This enduring CME activity offers education to augment your clinical competence in several areas, including:

  • Use of biomarkers to select patients with advanced cervical cancer for immune-based approaches
  • Integration of checkpoint inhibitors into the management of advanced cervical cancer
  • Mitigation of immune-related adverse events associated with immunotherapeutic approaches
  • Sequencing of multiple lines of therapy for patients with advanced cervical cancer

The format of this archived live broadcast is an in-studio panel discussion where the faculty briefly didactically present immunotherapy rationale and clinical trial data, after which they discuss and debate the practical application of this approach for patients with advanced cervical cancer. The panel also answers several questions submitted by viewers. The webcast has been divided into modules for your ease of access, and it brings conference-caliber education to the convenience of your screen!

Benefits of Participating

  • Insights into the use of biomarkers to select patients with advanced cervical cancer for immune-based approaches
  • Improved competence for integrating checkpoint inhibitors into the management of advanced cervical cancer
  • Strategies to mitigate immune-related adverse events associated with immunotherapeutic approaches
  • Opportunity to have your questions answered live by the faculty to gain expert insight into this difficult-to-treat tumor type

Acknowledgement of Commercial Support

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists and gynecologists who treat patients with cervical tumors. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cervical tumors may also participate.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

  • Describe the rationale for the development of immunotherapies in the setting of cervical cancer
  • Summarize outcomes from immunotherapy clinical trials conducted in patients with advanced cervical cancer
  • Use cases to illustrate where and how immunotherapy agents fit within the care of patients with advanced cervical cancer
  • Outline strategies to alleviate immune-related adverse events in patients with cervical cancer

Faculty, Staff, and Planners' Disclosures

Chair

Bradley J. Monk, MD, FACS, FACOG
Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Phoenix Creighton University School of Medicine at St. Joseph’s Hospital
Phoenix, AZ

Disclosure: Consultant: AbbVie, Advaxis, Amgen, Biodesix, Genmab, Gradalis, ImmunoGen, Immunomedics, Incyte, Mateon (formally Oxigene), Merck, Myriad, Perthera, Pfizer, Precision Oncology, Puma, Samumed, Takeda, VBL; Speaker/Consultant: AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, TESARO, Inc.

Faculty

Linda R. Duska, MD, MPH, FACOG
Professor of Obstetrics and Gynecology
University of Virginia
Charlottesville, VA
 
 

Disclosure: Grant/Research Support: Merck, Novartis (research funding to department); Consultant/Advisory Board: Merck, Genentech

Shannon N. Westin, MD, MPH, FACOG
Associate Professor
Department of Gynecologic Oncology and Reproductive Medicine
Director, Early Drug Development
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant/Research Support: AstraZeneca, Genentech, Clovis, Tesaro, Bayer, Novartis, Cotinga Pharmaceuticals; Consultant: AstraZeneca, Roche/Genentech, Clovis, Tesaro, Merck, Ovation, Medivation, OncLive, Medscape

Planner

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM
Professor-in-Residence & Interim Division Director
Department of Obstetrics & Gynecology
The University of California, Irvine
Orange, CA

Disclosure: Grant/Research Support: AstraZeneca, AbbVie, Morphotek, Genentech, Regeneron, Merck; Consultant: Regeneron, Spectrum, Genentech, Que, Agenus, Tesaro, Clovis, AstraZeneca; Speaker's Bureau: Clovis, Tesaro

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By